9 results about "Thermogenesis" patented technology

This invention discloses a probiotic protein V2016 and its application in the preparation of drugs for treating obesity, belonging to the field of biomedical technology. This invention provides a probiotic protein V2016, the amino acid sequence of which is shown in SEQ ID NO.1. Verification has shown that protein V2016 can efficiently and stably bind to the intestinal receptor ICAM-2, thereby significantly upregulating GLP-1 expression, mediating weight loss, reduced fat accumulation, and improved glucose tolerance; simultaneously, it can also reduce hepatic lipid deposition and inflammation, and promote thermogenesis activation in adipose tissue; at the intestinal microecological level, protein V2016 can improve the intestinal microenvironment, promote the enrichment of butyrate-producing bacteria in the intestine, thereby playing a role in regulating metabolism. In summary, the protein V2016 provided by this invention can be applied to the development of novel functional foods or weight-loss drugs.

The invention discloses application of hippuric acid in activation of brown adipose tissue heat production and prevention and treatment of obesity, and the application is realized by activating brown adipose tissue heat production, specifically, expression of uncoupling protein 1 in brown adipose tissue is up-regulated, heat production capacity under cold stimulation conditions is enhanced, weight gain and abnormal glucose and lipid metabolism are improved, and the purpose of preventing and treating obesity is achieved. The hippuric acid is preferably derived from walnut oil or metabolites thereof, and has a good application prospect.

This invention discloses the application of a Dickkopf-related protein 3 regulator in the preparation of metabolic regulation products. This invention is the first to propose and verify the novel functions of exogenous Dickkopf-related protein 3 in the regulation of adipose thermogenesis and the regulation of energy metabolism homeostasis in the body. It clarifies that it can promote lipid decomposition in adipocytes, enhance the thermogenic activity of adipocytes, promote the browning of white adipose tissue, and exert its effects through a non-UCP1-dependent pathway that promotes the stability of SERCA2b protein. This provides a new target and technical means for the intervention of lipid metabolism disorders such as obesity, type 2 diabetes, metabolic syndrome, and non-alcoholic fatty liver disease.

The inventors showed that intravenous administration of the small extracellular vesicles (sEVs) loaded with a plasmid encoding a dominant-negative mutant of NLRP3 under the control of the SF1 promoter (SF1-NLRP3-DN) slightly reduced body weight but did not modify food intake in atherosclerosis-prone ApoE knockout mice fed a high-fat diet, but induced an increase in brow adipose tissue (BAT) thermogenesis. Glucose tolerance was not affected after treatment with SF1-NLRP3-DN-loaded EVs. High-fat diet feeding induced an increase in the number of arrhythmias, as well as an increase in the onset of atrial fibrillation (AF) induced by transoesophageal stimulation, but also spontaneous arrhythmias that was not modified by the treatment with non-loaded EVs. Interestingly, EVs loaded with SF1-NLRP3-DN almost completely prevented both induced and spontaneous arrhythmias (conduction block) and AF. Finally, echocardiographic analyses showed that SF1-NLRP3-DN-loaded EVs did not induce any change in the structural and functional capacity of the heart. Accordingly, the present invention relates to the use of particles for the treatment of cardiac events associated with obesity.

The invention discloses bifidobacterium adolescentis and application of the bifidobacterium adolescentis in fat reduction. The bifidobacterium adolescentis is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC (China General Microbiological Culture Collection Center) No.31381. The bifidobacterium adolescentis has the effects of reducing the body fat rate, reducing weight, inhibiting the body weight rebound after weight loss, maintaining the weight loss effect, improving the blood fat and the like, promotes brown fat to produce heat and promotes white fat to be converted into brown fat, and meanwhile has high safety superior to that of weight-reducing drugs. In addition, when the medicine or food is used for treating and preventing obesity, the total cholesterol and total triglyceride levels are reduced, the liver function is improved, the pancreas health is maintained, the fat cell area is reduced, liver fat infiltration is reduced, the intestinal flora is regulated, and the inflammation level is reduced.

The present disclosure relates to the field of microbial therapy, and specifically to a product for preventing and / or treating obesity and a metabolic syndrome. The product includes a Lactobacillus acidophilus strain JYLA-126 and a coating solution thereof. A bacterial solution of the L. acidophilus strain JYLA-126 is coated with a bacterial coating solution to better transport the bacterial solution to the intestinal tract to exert therapeutic effects. The L. acidophilus strain JYLA-126 coating solution is used for intragastric treatment of obesity mice induced by high-fat diet. Various indicators show that the L. acidophilus strain JYLA-126 coating solution may effectively regulate intestinal microflora and maintain intestinal health. The coating solution improves liver glucose metabolism, reduces liver oxidative stress, improves liver lipid metabolism, and alleviates a liver inflammation level. This coating solution improves white adipose accumulation and promotes brown adipose thermogenesis, thereby achieving effective treatment of obesity and metabolic syndrome in mice.

The present invention relates to the technical field of biology. Provided is the use of an acetyl-CoA carboxylase gene in regulating porcine lipid metabolism, disclosing for the first time the involvement of the ACACA gene in regulating porcine beige adipocyte differentiation, and clarifying that inhibiting the expression of the ACACA gene can directly promote adipocyte thermogenesis. The present invention provides a new solution for the treatment of obesity and obesity-related diseases and a new approach for the breeding of cold-resistant low-fat livestock and poultry breeds.

The application discloses use of IAA and / or ILA in preparation of medicines, foods or skin care products for treating obesity, local fat accumulation and complications thereof. Obesity and complications thereof are effectively treated by a brand-new mechanism of inducing white adipose browning, promoting fat thermogenesis and increasing energy consumption of the body.

The present application provides a kind of nanobody NB21 targeted to LGR4 and its application in anti-obesity treatment.Specifically, the present application discloses a nanobody NB21 targeted to LGR4 and its derivative protein, gene sequence for coding them, expression vector and expression system for producing them.In addition, it is verified by in vitro and in vivo experiments that the nanobody NB21 targeted to block LGR4 has high affinity, high specificity, plays a biological function of promoting thermogenesis and reducing fat, and provides a new strategy for obesity treatment.